查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103603

萬古黴素市場：全球市場預測，2026-2032年

Vancomycin Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，萬古黴素市場規模將成長至 19.1 億美元，複合年成長率為 5.22%。

主要市場統計數據
基準年 2025 13.3億美元
預計年份：2026年 14億美元
預測年份 2032 19.1億美元
複合年成長率 (%) 5.22%

萬古黴素執行摘要：在治療嚴重革蘭氏陽性病菌感染中發揮關鍵作用

萬古黴素是一種極為重要的醣肽抗生素，主要用於治療嚴重的革蘭氏陽性病菌感染，例如抗藥性金黃色葡萄球菌（MRSA）感染和嚴重的艱難困難梭狀桿菌感染疾病。其持續的重要性體現在臨床上合理使用抗生素的優先事項、抗生素抗藥性監測的加強，以及在重症監護、外科手術、腫瘤科、透析、器官移植和長期護理機構中對可靠抗感染疾病治療的需求。需求趨勢受感染疾病負擔、診斷能力、基於指南的處方、治療藥物監測、注射劑供應的穩定性以及用於治療腸道感染疾病的口服製劑的可及性等因素的影響。隨著醫療保健系統中抗生素合理使用的加強，萬古黴素的使用不再僅限於廣泛的經驗性用藥，而是越來越注重精確的劑量設定、腎功能的安全管理、微生物學確認以及以治療結果為中心的治療路徑。

萬古黴素的使用、管理和供應可靠性發生了變革性變化。

隨著醫院從傳統的谷濃度監測轉向基於面積下面積（AUC）的給藥方案，萬古黴素的市場模式正在經歷結構性變化。此舉與廣泛採用的嚴重抗甲氧西林金黃色葡萄球菌（MRSA）感染疾病治療監測指南一致，旨在提高療效並降低腎毒性風險。快速分子診斷和合理的抗菌藥物使用方案正在縮短標靶治療的時間，並支持更適當的治療啟動、升級和停藥決策。同時，醫療相關感染預防、導管相關血流感染方案、術前預防管理以及艱難梭菌感染管理指南正在重塑該藥物在住院和門診環境中的使用。對於必需的注射用抗生素而言，供應鏈的韌性已成為一項策略重點，採購團隊專注於品質保證、冗餘備份、檢驗的儲存和分銷流程以及法規遵循。對無菌生產、藥物警戒和學名藥等效性的監管持續影響產品的可靠性和處方集信心。

人工智慧對萬古黴素最佳化的累積影響

人工智慧 (AI) 透過臨床決策支援、劑量最佳化、感染疾病監測和改善營運規劃，對萬古黴素生態系統產生了日益顯著的影響。 AI 驅動的藥物動力學工具整合了腎功能、體重、年齡、血清濃度數據、適應症嚴重程度和合併症情況等信息，支持個性化給藥，幫助臨床醫生根據不斷變化的治療監測建議調整治療方案。機器學習模型也被用於檢測敗血症風險、預測急性腎損傷、識別抗生素抗藥性徵兆以及確定微生物檢測的優先順序。在藥局營運方面，AI 可以提高關鍵抗生素的庫存可見性，減少浪費，並根據消耗模式、購買前置作業時間以及感染疾病爆發期間的使用變化預測缺貨。然而，安全實施 AI 需要檢驗的演算法、臨床醫生的監督、模型效能的透明度、資料隱私保護、區域調整以及與適當的抗生素使用管治相結合，以避免抗生素的不當使​​用。

亞太地區、歐洲、北美、拉丁美洲、非洲和中東的關鍵區域洞察

在亞太地區，醫院容量的顯著擴張、龐大的患者數量、抗菌藥物管理（IPSS）實踐成熟度的差異以及診斷投入的增加，都對萬古黴素的使用產生了影響，尤其是在中國、印度、日本、韓國、澳大利亞和東南亞國協。北美地區的特點是感染疾病指南成熟、治療監測廣泛、醫院IPSS實踐完善，並且對耐甲氧西林金黃色葡萄球菌（MRSA）和艱難梭菌感染的診療路徑有較高的認知。歐洲受益於協調一致的抗菌藥物抗藥性措施、藥物安全監測標準和已建立的醫院處方集，歐洲衛生當局推動跨境衛生安全、IPSS實踐和感染預防優先事項。在拉丁美洲，人們越來越重視醫療相關感染的管理和IPSS抗藥性監測，但公立和私立醫療系統獲得先進診斷技術和IPSS資源的機會存在差異。非洲面臨感染疾病負擔日益加重和檢測能力不均的雙重挑戰，因此，可靠的供應、品質有保證的學名藥以及合理用藥培訓對於萬古黴素的永續使用至關重要。在中東，尤其是在海灣合作理事會成員國的醫療保健系統中，擴大三級醫療保健基礎設施、發展醫療旅遊中心和投資感染控制方面取得了進展，同時，基於認證方案的數位醫院平台和品質計畫支持更標準化的抗菌藥物管治。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會等關鍵集團的分析

北約成員國受益於協調的醫療保健系統、緊急時應對計畫以及對基本抗菌藥物安全供應鏈的重視，這凸顯了在日常實踐和衛生安全情況下可靠獲取萬古黴素的重要性。七國集團（G7）國家通常擁有先進的診斷技術、完善的腎功能監測體系、嚴格的法律規範、基於指南的處方以及成熟的抗菌藥物綜合管理（IPS）基礎設施，支持基於AUC的給藥和適當的減重治療。金磚國家人口大規模，醫院需求量大，擁有國內藥品生產能力，並且對抗菌藥物抗藥性問題高度關注，因此品質保證、綜合監測和IPS實施至關重要。歐盟的特點是監管要求統一、抗菌藥物抗藥性計畫完善、藥物安全監測系統完善，以及醫院IPS實踐促進實證用藥和安全監測。東協市場呈現多元化的萬古黴素市場格局，這受到醫院網路不斷擴展、感染疾病監測現代化以及成員國之間治療藥物監測資源不均等因素的影響。海灣合作理事會國家已對三級醫療機構、數位醫療系統、感染預防計劃和基於認證系統的品質框架進行了大力投資，為基於方案的萬古黴素管理和以品質為中心的採購創造了機會。

針對主要萬古黴素市場的關鍵國家/地區特定見解。

中國持續加強抗菌藥物監管、醫院合理用藥管理、診斷能力、國內生產的品質監管。同時，美國在引入基於AUC的萬古黴素監測、合理用藥管理認證要求以及艱難梭菌感染臨床路徑標準化方面發揮著主導作用。日本擁有先進的醫院系統、老齡化人口帶來的感染疾病負擔以及強大的診斷能力；而印度則面臨著高感染疾病壓力和不斷成長的三級醫療需求，同時人們對合理用藥的認知也在不斷提高。德國、英國和法國擁有完善的醫院微生物學基礎設施、全國性的處方指南、藥物安全監測系統以及基於循證醫學的、謹慎的抗菌藥物使用。澳洲的萬古黴素使用遵循國家抗菌藥物指南、監測系統以及公立和私立醫療機構嚴格的抗菌藥物使用管治。韓國則將先進的診斷技術、三級醫療能力和感染控制重點結合。義大利和西班牙仍然是醫院抗生素使用的重要地區，當地的醫療機構、合理的抗生素使用政策和感染預防計畫都會影響藥物取得和監測實踐。在加拿大，省級處方集管理、感染控制和醫院監測尤其重要。同時，在俄羅斯，醫院抗感染藥物的使用受到區域醫療服務體系和應對抗生素抗藥性優先事項的影響。在巴西和墨西哥，人們越來越關注抗生素抗藥性和醫療相關感染的監測，藥物取得、檢測能力和公私醫療體系的差異都會影響臨床實務。

為萬古黴素行業領導者提供的實用建議

產業領導者應優先考慮臨床可靠性、供應保障以及與合理抗菌藥物使用政策的一致性。製造商和經銷商需要透過提高無菌生產品質、維持透明的供應連續性計劃以及提供有關法規遵從性、批間一致性、藥物安全監測系統和產品品管的文件，來支援醫院採購團隊。醫療服務提供者應在可行的情況下加速實施基於AUC的監測，整合藥師主導的給藥服務，並改善腎功能安全監測。政策制定者和醫療系統應擴大微生物檢測能力、抗菌藥物抗藥性報告和合理用藥教育，尤其是在檢查室資源有限的地區。數位醫療團隊應在實施人工智慧驅動的給藥和監測工具之前，檢驗在當地臨床患者群體中的有效性，並確保臨床醫生審核仍然是處方決策的核心。對於所有相關人員，最有效的策略是將萬古黴素定位為一種精準控制的基本抗生素，並以診斷、合理用藥方案、供應保障和可衡量的病人安全結果為支撐。

關於萬古黴素實證研究結果的調查方法

本執行摘要基於二手研究，並整合了來自檢驗的公共衛生、監管、臨床和科學資訊來源的證據，包括抗菌藥物抗藥性監測計畫、感染疾病指南、同行評審的臨床文獻、藥物警戒參考資料和醫院抗菌藥物服務標準。分析重點關注數據支援的主題，例如耐甲氧西林金黃色葡萄球菌（MRSA）管理、艱難梭菌治療實踐、藥物監測、腎臟安全性、無菌注射劑品質、抗菌藥物服務政策、醫療相關感染控制和診斷基礎設施。區域、群體和國家層面的見解均從醫療基礎設施、監管成熟度、診斷可近性、感染預防框架、抗菌藥物管治指標和基本藥物供應等方面進行解讀。為確保重點關注基於證據、與政策相關且可操作的發現，本摘要特意省略了市場規模調查方法、市場佔有率評估、收入估算和預測。

結論：萬古黴素的未來取決於精準性、合理管理和可靠的取得途徑。

萬古黴素仍是治療嚴重革蘭氏陽性病菌感染的重要抗生素，但其作用正從全院廣泛依賴轉向精準指導、管理式治療。改善治療效果的最大機會在於基於AUC的給藥方案、快速診斷、腎臟安全監測、品質保證的供應鏈以及人工智慧驅動的臨床決策工具。區域間在藥物管理能力、檢測基礎設施、監管、醫院投資以及基本藥物供應可靠性方面的差異將繼續影響萬古黴素的可近性和最佳化應用。將可靠的產品品質與實證用藥、數位化、抗生素抗藥性課責和病人安全管治相結合的相關人員，最有能力在現代醫療保健系統中支持永續的萬古黴素治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 萬古黴素市場：以劑型分類

  • 注射用凍乾粉
  • 口服製劑
  • 注射液

第8章：萬古黴素市場：依適應症分類

  • 困難梭狀桿菌感染疾病
  • 治療抗藥性金黃色葡萄球菌（MRSA）
  • 手術預防

第9章 萬古黴素市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：萬古黴素市場：依最終用戶分類

  • 門診手術中心
    • 多專科醫療中心
    • 單一專科醫療中心
  • 診所
    • 門診部
    • 專科診所
  • 醫院
    • 當地醫院
    • 三級醫療醫院

第11章 萬古黴素市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 萬古黴素市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 萬古黴素市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 萬古黴素市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Alvogen
  • Aphios Corporation
  • CJ CheilJedang Corporation
  • Eli Lilly and Company
  • Enanta Pharmaceuticals, Inc.
  • GlaxoSmithKline PLC
  • Helix BioMedix, Inc.
  • Innovation Pharmaceuticals Inc.
  • LegoChem Biosciences, Inc.
  • Lytix Biopharma AS
  • MGB Biopharma
  • Microbiotix, Inc.
  • MicuRx Pharmaceuticals
  • Nabriva Therapeutics GmbH
  • North China Pharmaceutical Group Co., Ltd.
  • NovaBay Pharmaceuticals, Inc.
  • NovoBiotic Pharmaceuticals, LLC
  • Oragenics, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sealife Pharma GmbH
  • VIANEX
  • Xellia Pharmaceuticals ApS
  • Zealand Pharma A/S
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
Product Code: MRR-C002B1C99629

The Vancomycin Market is projected to grow by USD 1.91 billion at a CAGR of 5.22% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.33 billion
Estimated Year [2026] USD 1.40 billion
Forecast Year [2032] USD 1.91 billion
CAGR (%) 5.22%

Vancomycin Executive Summary: Essential Role in Serious Gram-Positive Infection Care

Vancomycin is a critical glycopeptide antibiotic used primarily for serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus and severe Clostridioides difficile infection. Its continued relevance is supported by clinical stewardship priorities, rising antimicrobial resistance surveillance, and the need for reliable hospital anti-infective therapies across intensive care, surgical, oncology, dialysis, transplant, and long-term care settings. Demand patterns are shaped by infection burden, diagnostic capacity, guideline-based prescribing, therapeutic drug monitoring, injectable drug supply resilience, and the availability of oral formulations for intestinal infections. As health systems intensify antimicrobial stewardship, vancomycin use is increasingly defined by precision dosing, renal safety management, microbiology confirmation, and outcomes-focused treatment pathways rather than broad empiric use alone.

Transformative Shifts in Vancomycin Use, Stewardship, and Supply Reliability

The vancomycin landscape is undergoing structural change as hospitals move from conventional trough-based monitoring toward area-under-the-curve-guided dosing to improve efficacy while reducing nephrotoxicity risk, in line with widely adopted therapeutic drug monitoring guidance for serious MRSA infections. Rapid molecular diagnostics and antimicrobial stewardship programs are shortening time to targeted therapy, supporting more appropriate initiation, de-escalation, and discontinuation decisions. At the same time, healthcare-associated infection prevention, catheter-related bloodstream infection protocols, surgical prophylaxis controls, and C. difficile management guidelines are reshaping utilization across inpatient and outpatient care. Supply-chain resilience has become a strategic priority for essential injectable antibiotics, with procurement teams emphasizing quality assurance, redundancy, validated storage and distribution practices, and regulatory compliance. Regulatory scrutiny of sterile manufacturing, pharmacovigilance, and bioequivalence for generics continues to influence product reliability and formulary confidence.

Cumulative Impact of Artificial Intelligence on Vancomycin Optimization

Artificial intelligence is increasingly influencing the vancomycin ecosystem by improving clinical decision support, dose optimization, infection surveillance, and operational planning. AI-enabled pharmacokinetic tools can support individualized dosing by incorporating renal function, weight, age, serum concentration data, indication severity, and comorbidity profiles, helping clinicians align therapy with evolving therapeutic drug monitoring recommendations. Machine learning models are also being applied to detect sepsis risk, predict acute kidney injury, identify antimicrobial resistance signals, and prioritize microbiology review. In pharmacy operations, AI can improve inventory visibility for essential antibiotics, reduce wastage, and anticipate shortages based on consumption patterns, procurement lead times, and utilization changes during outbreaks. However, safe adoption requires validated algorithms, clinician oversight, transparent model performance, data privacy safeguards, local calibration, and integration with stewardship governance to avoid inappropriate antibiotic exposure.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East

In Asia-Pacific, high hospital capacity expansion, large patient volumes, variable antimicrobial stewardship maturity, and growing diagnostic investment shape vancomycin utilization, particularly in China, India, Japan, South Korea, Australia, and ASEAN economies. North America is characterized by mature infectious disease guidelines, widespread therapeutic drug monitoring, strong hospital stewardship infrastructure, and high awareness of MRSA and C. difficile care pathways. Europe benefits from coordinated antimicrobial resistance policy, pharmacovigilance standards, and established hospital formularies, with European health authorities advancing cross-border health security, antibiotic stewardship initiatives, and infection prevention priorities. Latin America shows increasing focus on healthcare-associated infection control and antimicrobial resistance surveillance, although access to advanced diagnostics and stewardship resources can vary across public and private systems. Africa faces a dual challenge of rising infectious disease burden and uneven access to laboratory capacity, making reliable supply, quality-assured generics, and stewardship training central to sustainable vancomycin use. The Middle East is seeing expanding tertiary care infrastructure, medical tourism hubs, and infection control investments, especially in GCC health systems, where digital hospital platforms and accreditation-driven quality programs are supporting more standardized antibiotic governance.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC

NATO countries benefit from health system coordination, preparedness planning, and emphasis on secure medical supply chains for essential antimicrobials, reinforcing the importance of dependable vancomycin access during routine care and health security events. G7 countries generally exhibit advanced diagnostics, established renal safety monitoring, strict regulatory oversight, guideline-based prescribing, and mature antimicrobial stewardship infrastructure that supports AUC-guided dosing and appropriate de-escalation. BRICS economies combine large population exposure, substantial hospital demand, domestic pharmaceutical production capabilities, and major antimicrobial resistance concerns, making quality assurance, surveillance integration, and stewardship implementation decisive. The European Union is defined by harmonized regulatory expectations, antimicrobial resistance action plans, pharmacovigilance systems, and hospital stewardship practices that promote evidence-based use and safety monitoring. ASEAN markets reflect a diverse vancomycin environment shaped by expanding hospital networks, infectious disease surveillance modernization, and uneven access to therapeutic drug monitoring across member states. The GCC demonstrates strong investment in tertiary hospitals, digital health systems, infection prevention programs, and accreditation-led quality frameworks, creating opportunities for protocol-driven vancomycin dosing and quality-focused procurement.

Key Country Insights Across Major Vancomycin Markets

China continues to strengthen antimicrobial regulation, hospital stewardship, diagnostic capacity, and domestic manufacturing quality oversight, while the United States leads in adoption of AUC-guided vancomycin monitoring, antimicrobial stewardship accreditation requirements, and C. difficile clinical pathway standardization. Japan demonstrates advanced hospital systems, aging population-related infection burden, and strong diagnostic capabilities, while India faces high infectious disease pressure and expanding tertiary care needs alongside increasing stewardship awareness. Germany, the United Kingdom, and France maintain robust hospital microbiology infrastructure, national prescribing guidance, pharmacovigilance systems, and restrained evidence-based antibiotic use. Australia's vancomycin use is guided by national antimicrobial guidelines, surveillance systems, and strong stewardship governance across public and private healthcare settings, while South Korea combines advanced diagnostics, tertiary hospital capacity, and infection control priorities. Italy and Spain remain important hospital anti-infective settings, with regional healthcare organization, stewardship policies, and infection prevention programs influencing access and monitoring practices. Canada emphasizes provincial formulary management, infection control, and hospital-based monitoring, while Russia's hospital anti-infective use is shaped by regional healthcare delivery and antimicrobial resistance priorities. Brazil and Mexico show growing attention to antimicrobial resistance and healthcare-associated infection surveillance, with access, laboratory capacity, and public-private system variation influencing clinical practice.

Actionable Recommendations for Vancomycin Industry Leaders

Industry leaders should prioritize clinical credibility, supply reliability, and stewardship alignment. Manufacturers and distributors need to strengthen sterile production quality, maintain transparent supply continuity plans, and support hospital procurement teams with documentation on regulatory compliance, batch consistency, pharmacovigilance readiness, and product quality controls. Healthcare providers should accelerate adoption of AUC-guided monitoring where feasible, integrate pharmacist-led dosing services, and improve renal safety surveillance. Policymakers and health systems should expand microbiology capacity, antimicrobial resistance reporting, and stewardship education, particularly in settings with limited laboratory access. Digital health teams should validate AI-enabled dosing and surveillance tools in local clinical populations before deployment and ensure clinician review remains central to prescribing decisions. Across all stakeholders, the most defensible strategy is to position vancomycin as a precision-managed essential antibiotic supported by diagnostics, stewardship protocols, supply assurance, and measurable patient safety outcomes.

Research Methodology for Evidence-Based Vancomycin Insights

This executive summary is developed through secondary research and evidence synthesis from verified public health, regulatory, clinical, and scientific sources, including antimicrobial resistance surveillance programs, infectious disease guidelines, peer-reviewed clinical literature, pharmacovigilance references, and hospital stewardship standards. The analysis prioritizes data-backed themes such as MRSA management, C. difficile treatment practices, therapeutic drug monitoring, renal safety, sterile injectable quality, antimicrobial stewardship policy, healthcare-associated infection control, and diagnostic infrastructure. Regional, group, and country insights are interpreted through healthcare infrastructure, regulatory maturity, diagnostic access, infection prevention frameworks, antibiotic governance indicators, and essential medicine supply considerations. The methodology deliberately excludes market sizing, market share assessment, revenue estimation, and forecasting to maintain focus on clinically grounded, policy-relevant, and operationally actionable intelligence.

Conclusion: Vancomycin's Future Depends on Precision, Stewardship, and Reliable Access

Vancomycin remains an indispensable antibiotic in the management of serious Gram-positive infections, but its role is evolving from broad hospital reliance toward precision-guided, stewardship-controlled therapy. The strongest opportunities for improving outcomes lie in AUC-based dosing, rapid diagnostics, renal safety monitoring, quality-assured supply chains, and AI-supported clinical decision tools. Regional differences in stewardship capacity, laboratory infrastructure, regulation, hospital investment, and essential medicine supply reliability will continue to influence how vancomycin is accessed and optimized. Stakeholders that combine dependable product quality with evidence-based use, digital enablement, antimicrobial resistance accountability, and patient safety governance will be best positioned to support sustainable vancomycin therapy in modern healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vancomycin Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Lyophilized Powder For Injection
  • 7.3. Oral Formulation
  • 7.4. Solution For Injection

8. Vancomycin Market, by Indication

  • 8.1. Introduction
  • 8.2. Clostridioides Difficile Infections
  • 8.3. Methicillin Resistant Staphylococcus Aureus Treatment
  • 8.4. Surgical Prophylaxis

9. Vancomycin Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral

10. Vancomycin Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
    • 10.2.1. Multi Specialty Centers
    • 10.2.2. Single Specialty Centers
  • 10.3. Clinics
    • 10.3.1. Outpatient Clinics
    • 10.3.2. Specialty Clinics
  • 10.4. Hospitals
    • 10.4.1. Community Hospitals
    • 10.4.2. Tertiary Care Hospitals

11. Vancomycin Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Vancomycin Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Vancomycin Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Vancomycin Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Alvogen
  • 16.2. Aphios Corporation
  • 16.3. CJ CheilJedang Corporation
  • 16.4. Eli Lilly and Company
  • 16.5. Enanta Pharmaceuticals, Inc.
  • 16.6. GlaxoSmithKline PLC
  • 16.7. Helix BioMedix, Inc.
  • 16.8. Innovation Pharmaceuticals Inc.
  • 16.9. LegoChem Biosciences, Inc.
  • 16.10. Lytix Biopharma AS
  • 16.11. MGB Biopharma
  • 16.12. Microbiotix, Inc.
  • 16.13. MicuRx Pharmaceuticals
  • 16.14. Nabriva Therapeutics GmbH
  • 16.15. North China Pharmaceutical Group Co., Ltd.
  • 16.16. NovaBay Pharmaceuticals, Inc.
  • 16.17. NovoBiotic Pharmaceuticals, LLC
  • 16.18. Oragenics, Inc.
  • 16.19. Pfizer Inc.
  • 16.20. Sanofi SA
  • 16.21. Sealife Pharma GmbH
  • 16.22. VIANEX
  • 16.23. Xellia Pharmaceuticals ApS
  • 16.24. Zealand Pharma A/S
  • 16.25. Zhejiang Hisun Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VANCOMYCIN MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VANCOMYCIN MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VANCOMYCIN MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VANCOMYCIN MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL VANCOMYCIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LYOPHILIZED POWDER FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LYOPHILIZED POWDER FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LYOPHILIZED POWDER FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL FORMULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL FORMULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL FORMULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOLUTION FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLUTION FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOLUTION FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SURGICAL PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SURGICAL PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SURGICAL PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTI SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTI SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTI SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SINGLE SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SINGLE SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SINGLE SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OUTPATIENT CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TERTIARY CARE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. NATO VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. NATO VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. NATO VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NATO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 130. NATO VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. NATO VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. NATO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. G7 VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. G7 VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 135. G7 VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. G7 VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC VANCOMYCIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GCC VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 171. GCC VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. GCC VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GCC VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL VANCOMYCIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. JAPAN VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. JAPAN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 199. JAPAN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. JAPAN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. JAPAN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. JAPAN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 203. JAPAN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. JAPAN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. INDIA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. INDIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. INDIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. INDIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. INDIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. INDIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 212. INDIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. INDIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 244. FRANCE VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. ITALY VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN VANCOMYCIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN VANCOMYCIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN VANCOMYCIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN VANCOMYCIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN VANCOMYCIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN VANCOMYCIN MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN VANCOMYCIN MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN VANCOMYCIN MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN VANCOMYCIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. GLOBAL VANCOMYCIN MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 315. GLOBAL VANCOMYCIN MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025